Zacks Investment Research upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a strong-buy rating in a research note issued to investors on Saturday, Zacks.com reports. Zacks Investment Research currently has $19.00 price objective on the stock.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
OXFD has been the topic of several other reports. ValuEngine upgraded Oxford Immunotec Global from a sell rating to a hold rating in a report on Wednesday, September 25th. TheStreet lowered Oxford Immunotec Global from a c- rating to a d+ rating in a report on Monday, July 15th. Piper Jaffray Companies set a $20.00 target price on Oxford Immunotec Global and gave the stock a buy rating in a report on Wednesday, September 18th. Cowen set a $20.00 target price on Oxford Immunotec Global and gave the stock a buy rating in a report on Tuesday, September 24th. Finally, BidaskClub upgraded Oxford Immunotec Global from a strong sell rating to a sell rating in a report on Saturday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $19.67.
OXFD stock traded down $0.12 during midday trading on Friday, reaching $16.69. 246,700 shares of the company’s stock traded hands, compared to its average volume of 175,306. The company has a 50-day simple moving average of $15.67 and a two-hundred day simple moving average of $14.58. The company has a quick ratio of 12.76, a current ratio of 13.35 and a debt-to-equity ratio of 0.03. The company has a market cap of $441.36 million, a price-to-earnings ratio of 32.73 and a beta of 0.42. Oxford Immunotec Global has a 1-year low of $11.88 and a 1-year high of $18.60.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Tuesday, November 5th. The company reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.09. The firm had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.23 million. Oxford Immunotec Global had a return on equity of 15.75% and a net margin of 199.21%. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.13) earnings per share. Equities research analysts forecast that Oxford Immunotec Global will post -0.17 EPS for the current year.
In other news, CEO Peter Wrighton-Smith sold 20,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $14.92, for a total value of $298,400.00. Following the sale, the chief executive officer now directly owns 404,538 shares in the company, valued at $6,035,706.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $16.45, for a total value of $49,350.00. Over the last 90 days, insiders sold 63,000 shares of company stock worth $972,650. Corporate insiders own 4.21% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Oxford Immunotec Global by 34.9% in the second quarter. Tower Research Capital LLC TRC now owns 2,734 shares of the company’s stock valued at $37,000 after purchasing an additional 708 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Oxford Immunotec Global by 218.9% in the third quarter. Quadrant Capital Group LLC now owns 1,805 shares of the company’s stock valued at $29,000 after purchasing an additional 1,239 shares in the last quarter. Aperio Group LLC bought a new stake in Oxford Immunotec Global during the second quarter worth about $42,000. JPMorgan Chase & Co. raised its holdings in Oxford Immunotec Global by 3.5% during the second quarter. JPMorgan Chase & Co. now owns 94,354 shares of the company’s stock worth $1,298,000 after acquiring an additional 3,157 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its holdings in Oxford Immunotec Global by 15.0% during the second quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after acquiring an additional 3,255 shares in the last quarter. Institutional investors own 94.03% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Read More: Example of operating income, EBIT and EBITDA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.